[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"effect-of-drug\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:effect-of-drug":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,77,97,127,144,165,191,221],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100560314","phase-4-efficacy-and-safety-of-remimazolam-besylate-for-sedation-in-post-non-cardiac-surgery-patients-requiring-mechanical-ventilation-100560314",false,"NCT06575530","Efficacy and Safety of Remimazolam Besylate for Sedation in Post-Non-Cardiac Surgery Patients Requiring Mechanical Ventilation","Efficacy and Safety of Remimazolam Besylate for Sedation in Post-Non-Cardiac Surgery Patients Requiring Mechanical Ventilation: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged between 18 and 64 years\n* Scheduled to undergo elective non-cardiac surgery\n* Planned for general anesthesia\n* With or without combined regional nerve blockade\n* Admitted to the ICU with endotracheal intubation post-surgery\n* With an anticipated duration of postoperative mechanical ventilation greater than 24 hours\n* Clinically requiring light sedation( target RASS score 0 to -2)\n\nExclusion Criteria:\n\n* Undergoing intracranial surgery, or having a history of severe neurological or spinal cord diseases\n* Pre-existing history of schizophrenia, epilepsy, or Parkinson's disease\n* Inability to communicate preoperatively due to coma, severe dementia, or language barriers\n* Preoperative .cardiac insufficiency or severe cardiac arrhythmias\n* Severe hepatic impariment( Child-Pugh class C)\n* Severe renal impariment\n* Preoperative( within 24 hours prior to surgery) or intraoperative administration of dexmedetomidine or remimazolam\n* Pregnancy or lactation\n* Participation in any clinical trial involving investigational drugs within 30 days prior to enrollment\n* Any other conditions deemed by the investigators to render the patient unsuitable for study participation\n* Refusal to provide written informed consent","ALL","18 Years","64 Years",{"count":20,"type":21},306,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","A multi-center, prospective, randomized, double-blind, active-controlled, no-inferiority clinical trial conducted across 5 tertiary medical centers in China. The objective of this RCT is to evaluate the sedative efficacy and safety profile of remimazolam besylate compared with dexmedetomidine in patients requiring mechanical ventilation following non-cardiac surgery. The study hypothesized that remimazolam besylate is non-inferior to dexmedetomidine regarding the primary efficacy outcome.",[27,28,29,30,31,32],"Effect of Drug","Adverse Drug Event","Mechanical Ventilation Complication","Critical Illness","Surgery","Sedation","RECRUITING","2026-06-13",{"date":36,"type":37},"2026-06-16","ACTUAL",{"date":39,"type":37},"2025-01-20",{"date":41,"type":21},"2026-06-30",{"name":43,"class":44},"Beijing Shijitan Hospital, Capital Medical University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100595827","effects-of-salbutamol-in-athletes-and-implications-for-screening-and-sports-100595827","NCT07037511","Effects of Salbutamol in Athletes and Implications for Screening and Sports","Physiological, Sensory and Ergogenic Effects of Salbutamol - Implications for Athletic Screening and β2 Agonist Use in Sport","Inclusion Criteria:\n\n* Aerobic capacity (V̇O2max) greater than 120% predicted\n* Body mass index (BMI) \\> 18 and \\\u003C 30 kg\u002Fm2\n* Ability to read and understand English\n* Currently training and\u002For competing in endurance sports (i.e. running or cycling)\n\nExclusion Criteria:\n\n* Smoking history or currently smoking. Currently smoking is defined as regular use of cigarettes or cannabis at any point in the past year. History of smoking is defined as smoking more than 1 pack year for cigarettes or the equivalent in cannabis use measured as puffs per day \u002F 200 (number of puffs in a pack of cigarettes).\n* Use of cannabis within the past 30 days or has a smoking history of at least 1 pack year.\n* Use of vaping devices or e-cigarettes in the past 30 days, or has used them more than 10 times in their lifetime.\n* History or current symptoms of cardiopulmonary disease (excluding controlled asthma)\n* Contraindications to exercise testing defined as anything that would prevent exercise under proper and safe conditions (e.g., a problem with the heart or lungs, muscle)\n* Neuromuscular or musculoskeletal condition",true,"55 Years",{"count":56,"type":21},64,[58],"NA","β2-Agonists, commonly used to treat asthma, have also been used by athletes to enhance performance, leading to their ban by the International Olympic Committee in 1972. Research has shown non-asthmatics receive no benefit from these drugs at therapeutic dosages; however, many elite athletes still use them, and asthmatic athletes often win more Olympic medals. In some non-asthmatics, β2-agonists may improve breathing limitations during high intensity exercise, which may improve performance. Therefore, we aim to examine if there is a select group of non-asthmatic individuals who experience breathing limitations that may receive benefit from β2-agonists.",[61,62,27],"Asthma","Healthy",[64,65,66,67],"Exercise Physiology","Expiratory Flow Limitation","Non-Asthmatics","Beta2-Agonists","2026-03-11",{"date":70,"type":37},"2026-03-13",{"date":72,"type":37},"2025-10-30",{"date":74,"type":21},"2030-12-31",{"name":76,"class":44},"University of British Columbia",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":45},"100552943","phase-4-compare-the-efficacy-and-outcome-between-fentanyl-and-morphine-as-analgo-sedation-in-mechanically-ventilated-patients-100552943","NCT06479655","Compare the Efficacy and Outcome Between Fentanyl and Morphine as Analgo-sedation in Mechanically Ventilated Patients","Inclusion Criteria:\n\n* Age \\>18 years old\n* Patients who are expected by the ICU team to require invasive mechanical ventilation in ICU for at least more than 24 hours and for whom the ICU team decides to initiate continuous infusion of sedation\n* A patient who was ventilated and sedated not more than 12 hours before ICU admission.\n\nExclusion Criteria:\n\n* Patients with chronic use of narcotics\n* Patients with chronic liver failure or end-stage renal failure\n* Patients with severe chronic neurocognitive dysfunction\n* Patients with drug overdose\n* Patients with a known allergy to either morphine or fentanyl\n* Patients who are receiving neuromuscular blockers\n* Patients who are pregnant\n* Patients who are diagnosed to have severe traumatic brain in",{"count":84,"type":21},116,[24],"The primary aim of this clinical trial is to compare the effectiveness of fentanyl vs morphine as analgosedation in mechanically ventilated adult patients in the ICU. This study also aims to compare the outcomes of patients between the two groups.\n\nThe main questions it aims to answer are :\n\n1. Does propofol and fentanyl infusion as analgo-sedation achieve targeted sedation score at 12 and 24 hours compared to propofol and morphine infusion in mechanically ventilated adult patients in the intensive care unit (ICU)?\n2. Is there a difference between the proportion of patients requiring rescue sedation dose between the fentanyl and morphine groups?",[27],"2025-09-30",{"date":90,"type":37},"2025-10-06",{"date":92,"type":37},"2024-07-15",{"date":94,"type":21},"2025-12-30",{"name":96,"class":44},"Universiti Sains Malaysia",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":104,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":45},"100552948","phase-4-efficacy-of-solifenacin-or-mirabegron-with-local-estrogen-versus-combination-pharmacotherapy-for-overactive-bladder-100552948","NCT06479720","Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","Efficacy and Safety of Solifenacin or Mirabegron With Local Estrogen Versus Combination Treatment With Mirabegron and Solifenacin for Refractory Overactive Bladder","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment\n* Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension\n* Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.","FEMALE","40 Years","90 Years",{"count":108,"type":21},300,[24],"To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder",[27,112],"Urinary Bladder, Overactive",[114,115,116,117],"Detrusor overactivity","Combined pharmacotherapy","Estrogens","Effectiveness","2025-05-06",{"date":120,"type":37},"2025-05-09",{"date":122,"type":37},"2022-06-16",{"date":124,"type":21},"2026-12-31",{"name":126,"class":44},"Mackay Memorial Hospital",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":104,"minAge":105,"maxAge":106,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":143,"locationsCount":45},"100531246","phase-4-efficacy-of-combined-pharmacotherapy-versus-solifenacin-with-vaginal-estrogen-cream-for-women-with-detrusor-overactivity-100531246","NCT06197295","Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","Efficacy and Safety of Solifenacin Combined With Mirabegron Versus Solifenacin With Vaginal Estrogen Cream for the Treatment of Detrusor Overactivity","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment\n* Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension\n* Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.\n* Women who were on hormone replacement therapy within 3 months were also excluded from the study",{"count":135,"type":21},200,[24],"To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.",[112,27],[114,115,116,117],{"date":120,"type":37},{"date":122,"type":37},{"date":124,"type":21},{"name":126,"class":44},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":104,"minAge":151,"maxAge":106,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":45},"100513700","phase-4-evaluation-the-efficacy-between-botox-injection-and-combination-pharmacotherapy-in-patients-with-detrusor-overactivity-100513700","NCT05968885","Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","Evaluation of the Efficacy and Urodynamic Outcomes Between Intradetrusor onabotulinumtoxinA Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with either anti-muscarinics or β3-adrenoceptor agonists were enrolled for prospective study\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment","20 Years",{"count":108,"type":21},[24],"To investigates the effects of botulinum toxin type A bladder injection compared to combined pharmacotherapy with Mirabegron and Solifenacin.",[112,156,27],"Urodynamics",[114,158,115,159,117],"Urodynamic study","Botulinum Toxins",{"date":120,"type":37},{"date":162,"type":37},"2021-10-01",{"date":124,"type":21},{"name":126,"class":44},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":181,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100573155","early-phase-1-efficacy-of-biological-therapy-in-pediatric-inflammatory-bowel-disease-100573155","NCT06742606","Efficacy of Biological Therapy in Pediatric Inflammatory Bowel Disease","Inclusion Criteria:\n\nPatients fulfilling modified Porto criteria for diagnosis of IBD including clinical features, laboratory, radiological and pathological findings.\n\nPatients initially severely diseased or in relapse and planned to start or change biological therapy.\n\nExclusion Criteria:\n\nPatients already on biological therapy and controlled. Patients with known humeral or cell mediated immunodeficiency.\n\nEthical","1 Month","16 Years",{"count":174,"type":21},40,[176],"EARLY_PHASE1","Compare efficacy of different biologicals in induction of remission including clinical, laboratory and histopathological remission.",[27],[180],"biological therapy , IBD","NOT_YET_RECRUITING","2024-12-18",{"date":184,"type":37},"2024-12-19",{"date":186,"type":21},"2025-01-15",{"date":188,"type":21},"2026-12-13",{"name":190,"class":44},"Ain Shams University",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":45},"100559337","phase-4-comparing-trypsin-chymotrypsin-and-naproxen-sodium-for-post-endodontic-treatment-pain-100559337","NCT06562816","Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain","Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Both male and female, healthy patients (ASA class 1).\n* Patients between the age group of 18-45 years.\n* Patients who are appointed for endodontic treatment.\n* Maxillary or mandibular teeth diagnosed with symptomatic irreversible pulpitis based on delayed responses to vitality tests.\n\nExclusion Criteria:\n\n* Patients who will require emergency dental treatment.\n* Teeth with any form of peri-apical lesion will be excluded.\n* Patient who have taken analgesics within 24 hours prior to the treatment.\n* Patients with known hypersensitivity or allergy to any of the study medications.\n* Patients with any systemic disease such as uncontrolled diabetes, gastric ulcers, bleeding disorders, or cardiovascular problems.\n* Pregnant or lactating women and pediatric patients.","45 Years",{"count":200,"type":21},100,[24],"This study aims to compare the pain reduction efficacy of Trypsin-Chymotrypsin and Naproxen sodium after root canal treatment in patients with symptomatic irreversible pulpitis. A lot of patients suffer greatly from post endodontic treatment pain and have a fear of dental treatments due to the pain. Patients refuse to go to the dentists and neglect oral hygiene care. That's why it is very important to find an effective drug regimen to reduce this post treatment pain. The null hypothesis is that there will be no difference between the efficacy and mean pain scores of Trypsin-chymotrypsin and Naproxen Sodium for post-endodontic treatment pain. Conducted as a triple-blinded, parallel, randomized controlled trial, 100 patients will be randomly assigned to receive either Trypsin-Chymotrypsin or Naproxen sodium following standard root canal therapy. Pain levels will be assessed using a numerical rating scale at 1, 6, 12, and 24 hours post-treatment to evaluate the effectiveness of these two pain management modalities.",[27],[205,206,207,208,209,210,211],"Trypsin-Chymotrypsin","Naproxen Sodium","Symptomatic Irreversible Pulpitis","Acute Irreversible Pulpitis","Post-endodontic treatment pain","Root canal treatment","Proteolytic Enzyme","2024-10-31",{"date":214,"type":37},"2024-11-04",{"date":216,"type":37},"2024-08-16",{"date":218,"type":21},"2025-01-31",{"name":220,"class":44},"Dow University of Health Sciences",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":228,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":45},"100553405","early-phase-1-effect-of-captopril-on-gls-in-duchenne-myodystrophy-100553405","NCT06485661","Effect of Captopril on GLS in Duchenne Myodystrophy","Intermediate Term Effect of Captopril on Left Ventricle Global Longitudinal Strain in Patients With Duchenne Myodystrophy","Inclusion Criteria:\n\n* Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS \\\u003C -18% with minimum age of 6 years old.\n\nExclusion Criteria:\n\n* Any patient who refuses to sign an informed consent.\n* Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension.\n* Reduced ejection fraction below 50%.","MALE","6 Years",{"count":231,"type":21},20,[176],"To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DMD)",[27],"2024-07-13",{"date":237,"type":37},"2024-07-16",{"date":239,"type":37},"2024-01-01",{"date":241,"type":21},"2024-09-30",{"name":190,"class":44}]